Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:10 am
Author: Getaka|Social: XLinkedIn

Jubilant Pharmova Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹897.40Fairly Valued by 9.84%vs CMP ₹817.00

P/E (28.2) × ROE (9.6%) × BV (₹414.00) × DY (0.61%)

₹561.70Overvalued by 31.25%vs CMP ₹817.00
MoS: -45.5% (Negative)Confidence: 54/100 (Moderate)Models: 1 Under, 1 Fair, 6 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹905.4026%Under (+10.8%)
Graham NumberEarnings₹502.9918%Over (-38.4%)
DCFCash Flow₹126.9915%Over (-84.5%)
Net Asset ValueAssets₹414.038%Over (-49.3%)
EV/EBITDAEnterprise₹787.4210%Fair (-3.6%)
Earnings YieldEarnings₹271.608%Over (-66.8%)
ROCE CapitalReturns₹670.988%Over (-17.9%)
Revenue MultipleRevenue₹454.356%Over (-44.4%)
Consensus (8 models)₹561.70100%Overvalued
Key Drivers: Wide model spread (₹127–₹905) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 0.9%

*Investments are subject to market risks

Investment Snapshot

55
Jubilant Pharmova Ltd scores 55/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health61/100 · Moderate
ROCE 9.5% AverageROE 9.6% AverageD/E 0.54 ModerateInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -1.27% (6mo) SellingDII holding up 4.18% MF buyingPromoter holding at 47.7% Stable
Earnings Quality60/100 · Moderate
OPM stable around 15% SteadyWorking capital: 16 days (improving) Efficient
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +12% YoY GrowingProfit (4Q): -31% YoY Declining
Industry Rank50/100 · Moderate
P/E 28.2 vs industry 53.8 Cheaper than peersROCE 9.5% vs industry 16.4% Below peers3Y sales CAGR: 6% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:10 am

Market Cap 13,008 Cr.
Current Price 817
Intrinsic Value₹561.70
High / Low 1,250/784
Stock P/E28.2
Book Value 414
Dividend Yield0.61 %
ROCE9.54 %
ROE9.55 %
Face Value 1.00
PEG Ratio31.60

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Jubilant Pharmova Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Jubilant Pharmova Ltd 13,008 Cr. 817 1,250/78428.2 4140.61 %9.54 %9.55 % 1.00
Alembic Pharmaceuticals Ltd 13,308 Cr. 677 1,108/63520.1 2711.62 %13.0 %11.4 % 2.00
Caplin Point Laboratories Ltd 11,935 Cr. 1,570 2,397/1,50019.4 4160.38 %25.8 %22.7 % 2.00
Cohance Lifesciences Ltd 11,934 Cr. 312 1,250/26739.7 99.00.00 %14.9 %12.7 % 1.00
Granules India Ltd 15,242 Cr. 628 640/41228.0 1640.24 %15.1 %13.9 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Jubilant Pharmova Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1,5521,6781,5871,6801,6771,7591,7321,7521,8221,9291,9011,9662,122
Expenses 1,4081,4591,4191,4381,4591,4871,4801,4631,5351,5841,6111,6251,833
Operating Profit 144219168242218271252289287345290341289
OPM % 9%13%11%14%13%15%15%17%16%18%15%17%14%
Other Income 102191949-1514108-109124-19
Interest 51566266717371615653495056
Depreciation 942719097951019191919598105121
Profit before tax 9-862598101-5450014413020615419093
Tax % 285%16%76%37%34%15%4%29%23%27%34%37%40%
Net Profit -16-10066266-6248210210115110212056
EPS in Rs -0.98-6.150.403.924.19-3.6830.266.456.339.646.467.553.51

Last Updated: March 4, 2026, 5:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 5:09 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 5,7625,7515,7495,8617,5189,1115,9766,0996,1306,2826,7037,2347,918
Expenses 4,7635,1414,4934,5105,9957,3674,4284,6954,9805,5035,8026,0616,653
Operating Profit 9996101,2561,3521,5221,7441,5481,4031,1507799011,1731,266
OPM % 17%11%22%23%20%19%26%23%19%12%13%16%16%
Other Income -1738641936-2492252638-9-764165
Interest 337368371341284220200184145188272240208
Depreciation 281288347291415371340349382554382369419
Profit before tax 207405427388599041,2331,13363028170981644
Tax % 34%200%29%22%26%36%27%26%34%333%57%15%
Net Profit 138-40387575634577898836413-6573836430
EPS in Rs 6.84-3.6324.6036.1440.3536.0656.3952.4725.98-3.834.8452.6927.16
Dividend Payout % 43%-83%12%8%7%12%9%10%19%-130%102%9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-128.99%1067.50%48.58%10.26%-8.99%55.63%-6.90%-50.60%-115.74%212.31%1045.21%
Change in YoY Net Profit Growth (%)0.00%1196.49%-1018.92%-38.32%-19.25%64.62%-62.54%-43.69%-65.14%328.05%832.90%

Jubilant Pharmova Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:2%
5 Years:4%
3 Years:6%
TTM:8%
Compounded Profit Growth
10 Years:24%
5 Years:-10%
3 Years:10%
TTM:107%
Stock Price CAGR
10 Years:15%
5 Years:8%
3 Years:48%
1 Year:14%
Return on Equity
10 Years:10%
5 Years:6%
3 Years:1%
Last Year:10%

Last Updated: September 5, 2025, 8:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:30 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 15161616161616161616161616
Reserves 2,6112,4382,9513,4204,0714,7935,5884,7265,3035,3835,4186,2396,576
Borrowings 4,3954,7934,4934,0453,4694,8404,8082,8303,1923,6773,6642,7312,883
Other Liabilities 1,8421,3721,2801,4171,9021,6701,8981,1921,3191,8532,2403,5984,047
Total Liabilities 8,8648,6198,7408,8999,45711,31912,3108,7639,83010,92911,33812,58413,521
Fixed Assets 5,0994,9115,1045,1075,4015,6486,3404,6094,8715,1835,0915,1767,354
CWIP 4725976116846719017688971,0901,5622,1033,6302,344
Investments 34408510312411569241239256424445
Other Assets 3,2593,0712,9393,0063,2624,6545,1333,0173,6313,9284,1013,7353,778
Total Assets 8,8648,6198,7408,8999,45711,31912,3108,7639,83010,92911,33812,58413,521

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 7727831,0991,2681,3031,1221,5431,7848386619711,072
Cash from Investing Activity + -164-362-309-465-614-1,018-267-727-323-474-596512
Cash from Financing Activity + -414-503-843-686-901657-1,050-1,709-33-157-432-1,453
Net Cash Flow 194-82-52117-212761225-65248230-58132
Free Cash Flow 5294347608068194739751,270241-13583-38
CFO/OP 85%141%91%104%103%84%116%155%90%111%131%112%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow995.00606.00-3.00-3.00-2.00-3.00-3.00-1.00-2.00776.00898.00-1.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 515260635551794955565045
Inventory Days 200169207223177147463268308268220178
Days Payable 10799106137145106273124139160146158
Cash Conversion Cycle 144122162149879226819422416512465
Working Capital Days -92124504545627456575616
ROCE %11%6%13%15%15%16%15%12%10%3%7%10%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 50.67%50.67%50.67%50.67%50.67%50.67%50.67%50.67%50.67%47.67%47.67%47.67%
FIIs 23.22%23.20%23.20%20.29%19.06%19.50%17.94%16.96%17.23%17.40%16.56%15.96%
DIIs 1.62%1.63%1.64%2.89%3.77%4.06%5.66%6.99%7.05%9.52%10.53%11.23%
Government 1.24%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public 23.11%23.91%23.89%25.56%25.91%25.18%25.17%24.82%24.48%24.83%24.60%24.57%
Others 0.13%0.59%0.59%0.58%0.58%0.58%0.56%0.56%0.56%0.56%0.63%0.57%
No. of Shareholders 97,93593,37589,37686,58892,26481,99289,4561,02,44296,52699,67393,33690,133

Shareholding Pattern Chart

No. of Shareholders

Jubilant Pharmova Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 2,947,185 1.06 289.38N/AN/AN/A
Bandhan Small Cap Fund 2,084,564 1.06 204.681,967,8672026-02-23 03:11:265.93%
Kotak Multicap Fund 1,873,926 0.81 1841,842,6132026-01-24 23:50:511.7%
Bandhan Focused Fund 982,101 4.84 96.43955,2222026-02-23 08:23:412.81%
Kotak Special Opportunities Fund 650,000 4.48 63.82N/AN/AN/A
Kotak Contra Fund 578,400 1.12 56.79N/AN/AN/A
Aditya Birla Sun Life Small Cap Fund 500,687 1.03 49.16499,2542026-02-21 00:51:050.29%
HDFC Manufacturing Fund 500,000 0.47 49.1N/AN/AN/A
KotaK MNC Fund 360,000 1.8 35.35N/AN/AN/A
HDFC Pharma and Healthcare Fund 317,568 1.66 31.18N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 52.994.87-3.8326.0052.48
Diluted EPS (Rs.) 52.994.86-3.8326.0052.48
Cash EPS (Rs.) 76.2927.2529.9850.5573.70
Book Value[Excl.RevalReserv]/Share (Rs.) 395.88343.11338.91333.97297.85
Book Value[Incl.RevalReserv]/Share (Rs.) 395.88343.11338.91333.97297.85
Revenue From Operations / Share (Rs.) 457.88424.23394.85385.08383.10
PBDIT / Share (Rs.) 77.8861.3651.2073.3588.83
PBIT / Share (Rs.) 54.5537.1916.3849.3766.91
PBT / Share (Rs.) 62.099.270.9740.2354.01
Net Profit / Share (Rs.) 52.963.08-4.8526.5751.78
NP After MI And SOA / Share (Rs.) 53.134.88-3.8326.0052.51
PBDIT Margin (%) 17.0014.4612.9619.0423.18
PBIT Margin (%) 11.918.764.1412.8217.46
PBT Margin (%) 13.562.180.2410.4414.09
Net Profit Margin (%) 11.560.72-1.226.9013.51
NP After MI And SOA Margin (%) 11.601.15-0.976.7513.70
Return on Networth / Equity (%) 13.411.41-1.127.7817.62
Return on Capital Employeed (%) 8.136.082.779.3513.53
Return On Assets (%) 6.580.66-0.544.149.37
Long Term Debt / Equity (X) 0.340.580.570.460.54
Total Debt / Equity (X) 0.380.620.630.550.54
Asset Turnover Ratio (%) 0.590.590.590.010.37
Current Ratio (X) 1.652.052.122.202.81
Quick Ratio (X) 1.131.371.341.421.74
Inventory Turnover Ratio (X) 5.981.361.260.001.44
Dividend Payout Ratio (NP) (%) 9.48103.24-130.6019.230.00
Dividend Payout Ratio (CP) (%) 6.5817.3416.1510.000.00
Earning Retention Ratio (%) 90.52-3.24230.6080.770.00
Cash Earning Retention Ratio (%) 93.4282.6683.8590.000.00
Interest Coverage Ratio (X) 5.123.564.338.037.68
Interest Coverage Ratio (Post Tax) (X) 2.991.800.893.914.17
Enterprise Value (Cr.) 15436.4611426.806827.698114.6012743.97
EV / Net Operating Revenue (X) 2.131.701.091.322.09
EV / EBITDA (X) 12.5411.798.386.959.01
MarketCap / Net Operating Revenue (X) 1.951.340.701.011.78
Retention Ratios (%) 90.51-3.24230.6080.760.00
Price / BV (X) 2.251.650.821.162.28
Price / Net Operating Revenue (X) 1.951.340.701.011.78
EarningsYield 0.050.01-0.010.060.07

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Jubilant Pharmova Ltd. is a Public Limited Listed company incorporated on 21/06/1978 and has its registered office in the State of Uttar Pradesh, India. Company's Corporate Identification Number(CIN) is L24116UP1978PLC004624 and registration number is 004624. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 745.70 Cr. and Equity Capital is Rs. 15.90 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBhartiagram, Amroha District Uttar Pradesh 244223Contact not found
Management
NamePosition Held
Mr. Shyam S BhartiaChairman
Mr. Hari S BhartiaCo-Chairman
Mr. Priyavrat BhartiaManaging Director
Mr. Arjun Shanker BhartiaJoint Managing Director
Mr. Arvind ChokhanyWholeTime Director & Group CFO
Dr. Ramakrishnan ArulWhole Time Director
Dr. Harsh MahajanIndependent Director
Mr. Arun SethIndependent Director
Mr. Vivek MehraIndependent Director
Ms. Shivpriya NandaIndependent Director
Mr. Shirish G BelapureIndependent Director
Mr. Sushil Kumar RoongtaIndependent Director

FAQ

What is the intrinsic value of Jubilant Pharmova Ltd and is it undervalued?

As of 19 April 2026, Jubilant Pharmova Ltd's intrinsic value is ₹561.70, which is 31.25% lower than the current market price of ₹817.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (9.55 %), book value (₹414), dividend yield (0.61 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Jubilant Pharmova Ltd?

Jubilant Pharmova Ltd is trading at ₹817.00 as of 19 April 2026, with a FY2026-2027 high of ₹1,250 and low of ₹784. The stock is currently near its 52-week low. Market cap stands at ₹13,008 Cr..

How does Jubilant Pharmova Ltd's P/E ratio compare to its industry?

Jubilant Pharmova Ltd has a P/E ratio of 28.2, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Jubilant Pharmova Ltd financially healthy?

Key indicators for Jubilant Pharmova Ltd: ROCE of 9.54 % is on the lower side compared to the industry average of 16.35%. Dividend yield is 0.61 %.

Is Jubilant Pharmova Ltd profitable and how is the profit trend?

Jubilant Pharmova Ltd reported a net profit of ₹836 Cr in Mar 2025 on revenue of ₹7,234 Cr. Compared to ₹413 Cr in Mar 2022, the net profit shows an improving trend.

Does Jubilant Pharmova Ltd pay dividends?

Jubilant Pharmova Ltd has a dividend yield of 0.61 % at the current price of ₹817.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Jubilant Pharmova Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports